Literature DB >> 11399686

Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.

G Fink1, T Krelbaum, A Yellin, D Bendayan, M Saute, M Glazer, M R Kramer.   

Abstract

OBJECTIVE: To determine the characteristic features and outcome of pulmonary carcinoid tumors in Israel.
METHODS: Retrospective analysis of the clinicopathologic data and outcome of patients from four major hospitals in Israel in the last 20 years.
RESULTS: There were 142 cases of pulmonary carcinoid tumors: typical (n = 128) and atypical (n = 14). We calculated an annual incidence of about 2.3 to 2.8 cases per 1 million population. The ratio of female to male patients was 1.6:1. The prevalence of smoking was similar to the general population in patients with typical carcinoids and twice as high in the atypical group. Bronchial obstruction was the cause of most of the presenting symptoms and signs and included obstructive pneumonitis, pleuritic pain, atelectasis, and dyspnea (41%). Carcinoid syndrome was extremely rare and occurred in only one patient with metastatic disease. Most of the tumors (68%) arose in the major bronchi. Diagnosis was made using fiberoptic bronchoscopy in 52% of patients without evidence of endobronchial hemorrhage. Nodal involvement and distant metastases occurred in 57% and 21%, respectively, in the atypical group, and 10% and 3%, respectively, in the typical group. The treatment of choice was surgical: lobectomy (56%) or pneumonectomy (16%). The respective 5-year survival rates for patients with typical and atypical tumors were 89% and 75% (not significant), and the 10-year survival rates were 82% and 56% (p < 0.05). A review of large series from the literature is presented.
CONCLUSION: Pulmonary carcinoid is an uncommon tumor in the Israeli population. With early diagnosis and aggressive surgical therapy, long-term prognosis is excellent.

Entities:  

Mesh:

Year:  2001        PMID: 11399686     DOI: 10.1378/chest.119.6.1647

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  95 in total

1.  [Neuroendocrine carcinoma of the lung: a diagnostic and therapeutic challenge].

Authors:  Claudia Böttger; Arne Warth; Peter P Nawroth; Berend Isermann
Journal:  Med Klin (Munich)       Date:  2010-04

2.  Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.

Authors:  Tarun Jindal; Arvind Kumar; Balasubramanian Venkitaraman; Roman Dutta; Rakesh Kumar
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

3.  Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience.

Authors:  Ryan F Herde; Kristine E Kokeny; Chakravarthy B Reddy; Wallace L Akerley; Nan Hu; Jonathan P Boltax; Ying J Hitchcock
Journal:  Am J Clin Oncol       Date:  2018-01       Impact factor: 2.339

4.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

5.  [Pulmonary carcinoid tumors].

Authors:  H Prosch
Journal:  Radiologe       Date:  2017-05       Impact factor: 0.635

6.  Is the clinical course of laryngeal typical carcinoid tumor indolent?

Authors:  Alfio Ferlito; Kenneth O Devaney; Jennifer L Hunt; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-09-08       Impact factor: 2.503

7.  Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas.

Authors:  Naama Peltz-Sinvani; Ruth Percik; Inbal Uri; Sapir Kon Kfir; Amir Tirosh; Amit Tirosh
Journal:  Endocrine       Date:  2021-05-12       Impact factor: 3.633

Review 8.  [Resection concepts for early stage neuroendocrine tumors of the lungs and bronchi].

Authors:  T Ploenes; C Aigner
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

9.  Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid.

Authors:  Balasubramanian Venkitaraman; Sellam Karunanithi; Arvind Kumar; G C Khilnani; Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

10.  Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre.

Authors:  Linda Skibsted Kornerup; Gitte Dam; Henning Gronbaek
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.